Stock ALZ ALZINOVA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alzinova AB

Equities

ALZ

SE0007413455

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.75 SEK +8.02% Intraday chart for Alzinova AB +28.68% -42.34%
Jul. 09 Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study CI
Jun. 18 Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study CI

Valuation

Fiscal Period: December 2020 2021 2023 2024 2025 2026
Capitalization 1 117.6 101.6 135.2 77.93 - -
Enterprise Value (EV) 1 117.6 73.56 113.1 -43.87 77.93 77.93
P/E ratio -18.8 x -13.4 x -7.4 x 3.5 x -0.18 x -0.18 x
Yield - - - - - -
Capitalization / Revenue - - 501 x 1.51 x - -
EV / Revenue - - 419 x -0.85 x - -
EV / EBITDA - -9.78 x - -4.39 x -0.93 x -0.93 x
EV / FCF - -2.71 x -3.25 x -11 x -0.93 x -0.93 x
FCF Yield - -36.9% -30.8% -9.12% -108% -108%
Price to Book - - - - - -
Nbr of stocks (in thousands) 15,267 15,776 44,531 44,531 - -
Reference price 2 7.700 6.440 3.035 1.750 1.750 1.750
Announcement Date 2/25/21 2/24/22 2/28/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - 0.27 51.5 - -
EBITDA 1 - -7.519 - - 10 -84 -84
EBIT 1 - -7.519 - -16.52 10 -84 -84
Operating Margin - - - -6,119.26% 19.42% - -
Earnings before Tax (EBT) 1 - -7.552 -13.09 -16.48 89 - -
Net income 1 -6.5 -7.552 -13.09 -16.48 82 - -
Net margin - - - -6,103.7% 159.22% - -
EPS 2 -0.4100 -0.4800 - -0.4100 0.5000 -10.00 -10.00
Free Cash Flow 1 - -27.14 - -34.82 4 -84 -84
FCF margin - - - -12,895.19% 7.77% - -
FCF Conversion (EBITDA) - - - - 40% - -
FCF Conversion (Net income) - - - - 4.88% - -
Dividend per Share - - - - - - -
Announcement Date 2/25/21 2/24/22 2/23/23 2/28/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 28 - 22 122 - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -27.1 - -34.8 4 -84 -84
ROE (net income / shareholders' equity) - - - -15% 39% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 2/25/21 2/24/22 2/23/23 2/28/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Alzinova AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALZINOVA AB Stock Alzinova AB
-42.34% 7.4M
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALZ Stock
  4. Financials Alzinova AB